It has taken years of research to develop a MenB vaccine, but in March 2014 a vaccine was recommended for routine use in babies aged 2, 4 and 12 months by UK government advisors
, the Joint Committee on Vaccination and Immunisation (JCVI).
This was a major step forward. Our analysis provided crucial evidence
to counter the JCVI’s initial conclusion that the vaccine was unlikely to be cost effective. Our members who took part in a study about the family impact of meningitis and septicaemia gave compelling evidence which was a key component of our response.
Your support has been crucial. Thank you for enabling us to keep the issue high on the political agenda by signing petitions
calling for the introduction of the vaccine. Two petitions were delivered to Downing Street totalling more than 50,000 signatures to which Health Secretary Jeremy Hunt personally responded
We would also like to thank the 330+ leading clinicians who supported a letter to Mr Hunt
we organised, led by Dr Simon Nadel, and published in the Times.
However, after the vaccine recommendation in March, negotiations with the manufacturer began in July, and are still inconclusive, leading us to believe they have stalled.
Throughout the process we have repeatedly expressed our concerns that cost effectiveness analysis undervalues the impact of this disease
Even now, as price negotiations continue, our genome library is providing new evidence which supports increased value of the MenB vaccine to UK children and increases the urgency for its introduction. A particularly deadly strain of MenW
, identified by our genome library as ST-11, is on the rise and the MenB vaccine would protect against it.
We need to keep the pressure up for the introduction of the MenB vaccine in the UK.
Many of you have already paid a very high price and before others succumb to MenB - a devastating yet preventable disease - we are pushing for price negotiations be concluded swiftly so that the vaccine can be offered to UK infants without delay and, in November, we wrote to Mr Hunt
expressing our concerns about the delay.